Liv-52 Attenuates Erlotinib-Induced Liver Injury via Modulation of Oxidative Stress, Inflammation, and Apoptosis in Rats

ArticleAçık Erişim

Özet

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is widely used in cancer therapy; however, hepatotoxicity limits its clinical use. This study investigated the protective effects of Liv-52, a polyherbal hepatoprotective formulation, against erlotinib-induced hepatotoxicity in rats and compared its efficacy with melatonin. The animals (n = 24, Wistar albino rats) were randomly categorized into four groups: healthy (HG), erlotinib (ERG), Liv-52 + erlotinib (LEG), and melatonin + erlotinib (MEG). Liv-52 (50 mg/kg/day, orally) and melatonin (10 mg/kg/day, orally) were administered once daily for two weeks. Erlotinib (10 mg/kg, orally) was given every other day to ERG, LEG, and MEG groups for two weeks. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) were measured. Hepatic malondialdehyde (MDA), total glutathione (tGSH), superoxide dismutase (SOD), and catalase (CAT) levels were analyzed. Additionally, double immunofluorescence staining was performed to evaluate apoptotic (poly[ADP-ribose] polymerase-1 [PARP-1], apoptosis-inducing factor [AIF]), inflammatory (cyclooxygenase-2 [COX-2]), and anti-inflammatory (interleukin-10 [IL-10]) biomarkers in liver tissues. Histopathological examination was also conducted to assess structural alterations. Erlotinib significantly increased MDA, ALT, AST, and LDH while decreasing tGSH, SOD, and CAT (p < 0.001). Strong immunoreactivity for PARP-1, AIF, IL-10, and COX-2, as well as severe hydropic degeneration and necrosis, was observed in ERG (p < 0.05). Both Liv-52 and melatonin significantly ameliorated biochemical, histopathological, apoptotic, and inflammatory alterations (p < 0.05). Notably, Liv-52 demonstrated superior hepatoprotective efficacy compared to melatonin. These findings indicate that Liv-52 effectively attenuates erlotinib-induced hepatotoxicity by modulating oxidative stress, inflammatory responses, and apoptotic pathways, thereby preserving liver function and structural integrity. © 2026 by the authors.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/10481Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.3390/ijms27093817Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorBulut, Seval
dc.contributor.authorAltuner, Durdu
dc.contributor.authorSuleyman, Bahadir
dc.contributor.authorMammadov, Renad
dc.contributor.authorOzkaraca, Mustafa
dc.contributor.authorGungor, Ali
dc.contributor.authorKuzucu, Mehmet
dc.contributor.authorHendem, Engin
dc.contributor.authorSuleyman, Halis
dc.date.accessioned2026-10-18T20:25:41.590622548Z
dc.date.available2026-10-18T20:25:41.590622548Z
dc.date.issued2026
dc.description.abstractErlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is widely used in cancer therapy; however, hepatotoxicity limits its clinical use. This study investigated the protective effects of Liv-52, a polyherbal hepatoprotective formulation, against erlotinib-induced hepatotoxicity in rats and compared its efficacy with melatonin. The animals (n = 24, Wistar albino rats) were randomly categorized into four groups: healthy (HG), erlotinib (ERG), Liv-52 + erlotinib (LEG), and melatonin + erlotinib (MEG). Liv-52 (50 mg/kg/day, orally) and melatonin (10 mg/kg/day, orally) were administered once daily for two weeks. Erlotinib (10 mg/kg, orally) was given every other day to ERG, LEG, and MEG groups for two weeks. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) were measured. Hepatic malondialdehyde (MDA), total glutathione (tGSH), superoxide dismutase (SOD), and catalase (CAT) levels were analyzed. Additionally, double immunofluorescence staining was performed to evaluate apoptotic (poly[ADP-ribose] polymerase-1 [PARP-1], apoptosis-inducing factor [AIF]), inflammatory (cyclooxygenase-2 [COX-2]), and anti-inflammatory (interleukin-10 [IL-10]) biomarkers in liver tissues. Histopathological examination was also conducted to assess structural alterations. Erlotinib significantly increased MDA, ALT, AST, and LDH while decreasing tGSH, SOD, and CAT (p < 0.001). Strong immunoreactivity for PARP-1, AIF, IL-10, and COX-2, as well as severe hydropic degeneration and necrosis, was observed in ERG (p < 0.05). Both Liv-52 and melatonin significantly ameliorated biochemical, histopathological, apoptotic, and inflammatory alterations (p < 0.05). Notably, Liv-52 demonstrated superior hepatoprotective efficacy compared to melatonin. These findings indicate that Liv-52 effectively attenuates erlotinib-induced hepatotoxicity by modulating oxidative stress, inflammatory responses, and apoptotic pathways, thereby preserving liver function and structural integrity. © 2026 by the authors.
dc.identifier.doi10.3390/ijms27093817
dc.identifier.eissn1422-0067
dc.identifier.issn1661-6596
dc.identifier.issue9
dc.identifier.pmcidPMC13163866
dc.identifier.pmid42123402
dc.identifier.scopus2-s2.0-105038439759
dc.identifier.startpage3817
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/10481
dc.identifier.volume27
dc.identifier.wosWOS:001763625600001
dc.language.isoen
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectantioxidant
dc.subjectapoptosis
dc.subjecterlotinib
dc.subjectinflammation
dc.subjectLiv-52
dc.subjectmelatonin
dc.subjectAnimals
dc.subjectAntioxidants
dc.subjectChemical and Drug Induced Liver Injury
dc.subjectErlotinib Hydrochloride
dc.subjectLiver
dc.subjectMale
dc.subjectOxidative Stress
dc.subjectPlant Extracts
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectalanine aminotransferase
dc.subjectapoptosis inducing factor
dc.subjectaspartate aminotransferase
dc.subjectcatalase
dc.subjectcyclooxygenase 2
dc.subjectglutathione
dc.subjectinterleukin 10
dc.subjectlactate dehydrogenase
dc.subjectliv 52
dc.subjectmalonaldehyde
dc.subjectnicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase 1
dc.subjectsuperoxide dismutase
dc.subjectplant extract
dc.subjectalanine aminotransferase blood level
dc.titleLiv-52 Attenuates Erlotinib-Induced Liver Injury via Modulation of Oxidative Stress, Inflammation, and Apoptosis in Rats
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus0
rdl.citation.wos0
rdl.departmentDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey. | Department of Molecular Biology, Faculty of Arts and Sciences, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey. | Department of Medical Oncology, Mengucek Gazi Education and Research Hospital, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)